We therefore reasoned that split dose IV/IP delivery of MRB provided the best strategy to promote oncolysis of IP ovarian tumors while also boosting MIS416 Vax responses and was used in subsequent therapeutic studies. The gene discussed is ROBO4; the disease is ovarian neoplasm.